{"entity":{"id":"amx-883","kind":"drug","name":"AMX-883","aka":[],"tldr":"AMX-883 is an experimental oral small-molecule targeted protein degrader from Amphista Therapeutics, in phase 1 trials for acute myeloid leukaemia and higher-risk myelodysplastic syndromes.","summary":"AMX-883 is an oral small-molecule targeted protein degrader (Targeted Glue) from Amphista Therapeutics. An oral degrader that uses the E3 ligase DCAF16 to destroy BRD9; in preclinical work this released the differentiation block in a broad range of AML models and was synergistic with venetoclax. Its furthest stage is phase 1, for acute myeloid leukaemia and higher-risk myelodysplastic syndromes. ClinicalTrials.gov registers it in one study linked below. FDA cleared the IND; phase 1 NCT07723703 recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Amphista Therapeutics: amphista.com","url":"https://amphista.com/pipeline/"},{"label":"Amphista Therapeutics: amphista.com","url":"https://amphista.com/pipeline/"},{"label":"Amphista Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07723703"},{"label":"ClinicalTrials.gov: trials of AMX-883","url":"https://clinicaltrials.gov/search?intr=AMX-883"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds-higher-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["amphista-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07723703"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AMX-883","modality":"Oral small-molecule targeted protein degrader (Targeted Glue)","mechanism":"An oral degrader that uses the E3 ligase DCAF16 to destroy BRD9; in preclinical work this released the differentiation block in a broad range of AML models and was synergistic with venetoclax.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/amx-883/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"}],"company":[{"id":"amphista-therapeutics","kind":"company","name":"Amphista Therapeutics","route":"/companies/amphista-therapeutics/"}],"trial":[{"id":"nct07723703","kind":"trial","name":"Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML","route":"/trials/nct07723703/"}]}}